SGLT2-is also appear to act on pancreatic α-cells, leading to an increase in glucagon secretion [36], which promotes β-oxidation of fatty acids, and consequently, reduces liver triglycerides and improves liver steatosis [36,37]. The gene discussed is SLC5A2; the disease is Hepatic steatosis.